# Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery

Study · id `cardio:ct-nct02334007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02334007](<https://clinicaltrials.gov/study/NCT02334007>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02334007

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT02334007. Randomized; quadruple masking; primary purpose prevention. Start 2015-09 (registry gives no type); primary completion 2018-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 1/2
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT02334007, source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)
- Start date: 2015-09 (registry gives no type) (ClinicalTrials.gov record NCT02334007, source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)
- Primary completion: 2018-09 (actual) (ClinicalTrials.gov record NCT02334007, source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)
- Completion: 2018-09 (actual) (ClinicalTrials.gov record NCT02334007, source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT02334007, source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02334007-2018-09-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
- Condition: Venous Thromboembolism
- Condition: Lung Neoplasms
- Condition: Pulmonary Embolism
- Intervention (Drug): LMWH: Dalteparin
- Intervention (Other): Placebo
- Lead sponsor: McMaster University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: McMaster University (`cardio:org-mcmaster-university`)

## Provenance

Content hash: dd70284344aa6560b27f6cfe7f8c24485cb337a43d621bc6b66d90d28d6f117e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
